CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

BACKGROUND: Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen to its a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Jennifer D., Comen, Elizabeth A., Reiner, Anne S., Orlow, Irene, Leong, Siok F., Liang, Xiaolin, Mellemkjær, Lene, Knight, Julia A., Lynch, Charles F., John, Esther M., Bernstein, Leslie, Woods, Meghan, Doody, David R., Malone, Kathleen E., Bernstein, Jonine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288916/
https://www.ncbi.nlm.nih.gov/pubmed/30526633
http://dx.doi.org/10.1186/s13058-018-1083-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288916/
https://www.ncbi.nlm.nih.gov/pubmed/30526633
http://dx.doi.org/10.1186/s13058-018-1083-y

Ejemplares similares